Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 213, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2020.113135
Keywords
Gemcitabine prodrugs; Hepatitis C virus; Liver-specific prodrugs; Hepatocellular carcinoma; Carboxylesterase; Therapeutic index
Categories
Funding
- Drug Discovery Institute at The Ohio State University
Ask authors/readers for more resources
Nucleoside analogs play an important role in the development of anti-viral and anti-cancer drugs. Liver-specific prodrugs of gemcitabine were synthesized to target HCV infection and hepatocellular carcinoma, showing potential therapeutic effects with reduced cytotoxicity in certain cancer cell lines. The prodrugs also exhibited inhibitory effects on HCV replicon and synergistic effects with other anti-HCV drugs, supporting their development as liver-specific therapeutics.
Many successful anti-viral and anti-cancer drugs are nucleoside analogs, which disrupt RNA and/or DNA synthesis. Here, we present liver-specific prodrugs of the chemotherapy drug gemcitabine (2',2'-difluorodeoxycytidine) for the treatment of hepatitis C virus (HCV) infection and hepatocellular carcinoma. The prodrugs were synthesized by introducing aromatic functional moieties to the cytosine 4-NH2 group of gemcitabine via amide bonds. The chemical modification was designed to i) enable passive diffusion across cellular membrane, ii) protect the prodrugs from inactivating deamination by cellular enzymes, and iii) allow release of active gemcitabine after amide hydrolysis by high levels of carboxylesterases in the liver. We found that many of our prodrugs exhibited similar toxicity as gemcitabine toward liver- and kidney-derived cancer cell lines but were 24- to 620-fold less cytotoxic than gemcitabine in breast- and pancreas-derived cancer cells, respectively. The prodrugs also inhibited an HCV replicon with IC50 values ranging from 10 nM-1.7 mu M. Moreover, many of the prodrugs had therapeutic index values of >10,000 and have synergetic effects when combined with other Food and Drug Administration-approved anti-HCV small molecule drugs. These characteristics support the development of gemcitabine prodrugs as liver-specific therapeutics. (C) 2020 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available